EP2595607A2 - Médicament d'administration orale contenant un mélange de silodosine et d'un copolymère basique - Google Patents
Médicament d'administration orale contenant un mélange de silodosine et d'un copolymère basiqueInfo
- Publication number
- EP2595607A2 EP2595607A2 EP11735435.7A EP11735435A EP2595607A2 EP 2595607 A2 EP2595607 A2 EP 2595607A2 EP 11735435 A EP11735435 A EP 11735435A EP 2595607 A2 EP2595607 A2 EP 2595607A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- silodosin
- pharmaceutically acceptable
- copolymer
- optionally
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- PNCPYILNMDWPEY-QGZVFWFLSA-N silodosin Chemical compound N([C@@H](CC=1C=C(C=2N(CCCO)CCC=2C=1)C(N)=O)C)CCOC1=CC=CC=C1OCC(F)(F)F PNCPYILNMDWPEY-QGZVFWFLSA-N 0.000 title claims abstract description 82
- 229960004953 silodosin Drugs 0.000 title claims abstract description 77
- 239000003814 drug Substances 0.000 title claims abstract description 62
- 229920001577 copolymer Polymers 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 150000003839 salts Chemical class 0.000 claims abstract description 41
- 239000000654 additive Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 23
- 239000002904 solvent Substances 0.000 claims description 23
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 17
- 238000001694 spray drying Methods 0.000 claims description 17
- 239000000945 filler Substances 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 8
- 238000001125 extrusion Methods 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 239000004094 surface-active agent Substances 0.000 claims description 8
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 5
- 239000000155 melt Substances 0.000 claims description 5
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 28
- 238000004519 manufacturing process Methods 0.000 abstract description 12
- 229920003134 Eudragit® polymer Polymers 0.000 description 18
- 239000002245 particle Substances 0.000 description 17
- 239000000546 pharmaceutical excipient Substances 0.000 description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 229940126701 oral medication Drugs 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000007903 gelatin capsule Substances 0.000 description 9
- 238000005469 granulation Methods 0.000 description 9
- 230000003179 granulation Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000003860 storage Methods 0.000 description 8
- 238000001035 drying Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000011877 solvent mixture Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 238000003825 pressing Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000004148 curcumin Substances 0.000 description 4
- 235000019700 dicalcium phosphate Nutrition 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229920002678 cellulose Chemical class 0.000 description 3
- 239000001913 cellulose Chemical class 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- -1 croscarmelose Substances 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000004898 kneading Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920000881 Modified starch Chemical class 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 2
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical class [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229920003118 cationic copolymer Polymers 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000007909 melt granulation Methods 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- WCFCPOKVQRVKAQ-UHFFFAOYSA-N propan-2-ol;propan-2-one;hydrate Chemical compound O.CC(C)O.CC(C)=O WCFCPOKVQRVKAQ-UHFFFAOYSA-N 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- DVQGVNABCBCXBX-UHFFFAOYSA-N 2,3-dihydro-1h-indole-7-carboxamide Chemical compound NC(=O)C1=CC=CC2=C1NCC2 DVQGVNABCBCXBX-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002101 Chitin Chemical class 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004368 Modified starch Chemical class 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical class OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical class [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Chemical class 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Chemical class 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical class [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000002583 male contraceptive agent Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920001521 polyalkylene glycol ether Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000004728 pyruvic acid derivatives Chemical class 0.000 description 1
- 229940064587 rapaflo Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000005029 sieve analysis Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 229940117958 vinyl acetate Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- a medicament for oral administration comprising a mixture of silodosin and a basic copolymer
- the invention relates to a medicament for oral administration comprising a mixture of silodosin or a pharmaceutically acceptable salt thereof and a basic copolymer. Furthermore, the present invention relates to methods for producing such an oral drug.
- Silodosin is the international generic name of the compound 1 - (3-hydroxypropyl) -5 - [(2R) - ( ⁇ 2- [2- [2- (2,2,2-trifluoroethoxy) phenoxy] ethyl ⁇ amino) propyl] indoline -7-carboxamide having the following chemical structural formula:
- Silodosin is a known drug used to treat the symptoms of benign prostatic hyperplasia (a benign enlargement of the prostate gland).
- silodosin is a c-rAdrenoreceptor antagonist which blocks the receptors located in the prostate gland and results in smooth muscle relaxation of the bladder neck, urethra, and prostate associated with facilitated Hama flow. Silodosin is therefore used in particular for the treatment of dysuria.
- silodosin has been proposed as a male contraceptive.
- silodosin The production of silodosin is disclosed, for example, in the basic patent EP 0 600 675, which also describes the use of silodosin for the treatment of dysuria.
- Drug-containing silodosin are currently commercially available, including under the brands Urief ® and Rapaflo ®.
- the currently marketed drugs are hard gelatin capsules.
- the production of drugs containing the active ingredient silodosin poses a number of difficulties, since silodosin is considered to be photosensitive and should not be exposed to high temperatures.
- silodosin is incompatible with a number of pharmaceutically acceptable additives which are often used in the manufacture of medicaments, and therefore undesirable degradation products are often produced in the production and storage of silodosin-containing medicaments.
- Corresponding problems are described, for example, in EP-A 1 574 215 (in which the older designation KMD-3213 is used for silodosin).
- EP-A 1 574 215 problems arise in the solubility of tablets with the active ingredient silodosin and, according to EP-A 1 574 215, it is also difficult to formulate silodosin with a lubricant.
- the mixing time of the capsule contents should have an influence on the release profile of the active ingredient.
- EP-A 1 574 215 discloses some special medicaments, in particular those in which D-mannitol is used as filler and magnesium stearate as lubricant.
- JP 2004-175796 discloses tablets disintegrating in the mouth and more particularly relates to the taste masking of unpleasant tasting active ingredients.
- Silodosin or KMD-32173 is one of several drugs.
- silodosin and in particular the salts of silodosin can be present in amorphous, but also in various polymorphic crystalline forms, as described, for example, in EP-A 1 541 554. Depending on the form, silodosin is more or less hygroscopic.
- Eudragit ® E is a basic copolymer which is prepared from methyl methacrylate, butyl methacrylate and dimethylaminoethyl methacrylate.
- the use of Eudragit ® E, which is commercially available for example as Eudragit ® E 100, Eudragit ® E PO or Eudragit ® E 12.5 was, so far been limited mainly to coatings for oral pharmaceutical forms that protect the drug against light and moisture. Furthermore, such coatings are used for drugs having an unpleasant taste or odor, and also for drug forms whose active ingredients are intended to be released in the stomach.
- US 6,063,399 also discloses that Eudragit ® E can be used in combination with an anionic copolymer and a plasticizer for the production of self-adhesive matrix systems for transdermal applications.
- WO 2006/0201 1 1 discloses pharmaceutical formulations containing acid-labile benzimidazole derivatives in combination with the basic copolymer Eudragit ® E include. The addition of Eudragit ® E stabilized the acid-labile benzimidazole derivatives. A possible stabilizing effect of the Eudragit ® E on light-sensitive and temperature-sensitive active substances can not be found in the publication.
- the drug should be easy and inexpensive to produce.
- the unpleasant taste of silodosine should be masked.
- the oral drugs with these mixtures do not have the problems of the prior art.
- the silodosin in these oral drugs is chemically very stable and the mixtures are processable with a very large number of conventional pharmaceutical additives without problems to an oral drug.
- the physical form of silodosin in the oral drug also preferably does not change during storage, and oral drugs with the mixtures of the invention have a reproducible, very rapid release of the active ingredient in the stomach, which does not change significantly during storage of the drug.
- a basic copolymer significantly reduces the decomposition of silodosin under the action of light and heat, so that the stability of a drug can be improved even under the action of light and heat.
- the basic copolymers which can be used according to the invention are known to the person skilled in the art.
- the basic copolymers may have as the basic group, for example, an amino group or a carboxylate group.
- the basic group in the copolymers, which are used according to the invention in admixture with silodosin or a pharmaceutically acceptable salt thereof an amino group, in particular a tertiary amino group.
- the amino group of the basic copolymer is usually protonated in solution so that the basic copolymer is a cationic copolymer and is also referred to in some references as a cationic copolymer.
- the invention also preferably involves a basic acrylate or methacrylate copolymer, which in turn preferably carries amino groups.
- Particularly preferred according to the invention is a copolymer with monomer units derived from methyl methacrylate, butyl methacrylate and dimethylaminoethyl methacrylate.
- Such basic copolymers are, for example commercially available under the trade name Eudragit ® E, in particular, it is the products Eudragit ® E 100, Eudragit ® E PO and Eudragit ® E 12.5.
- Silodosin or a pharmaceutically acceptable salt thereof may be used for the preparation of the oral medicine of the present invention, and the properties of the oral drug of the present invention are preferably independent of whether the drug or drug salt is used in an amorphous form or in a crystalline form or in a particular polymorphic form has been.
- the medicaments of the invention are extremely economical and easy to prepare and offer the galenic a great deal of freedom in the choice of possible pharmaceutically acceptable excipients and additives.
- the oral drugs according to the invention show excellent storage stability.
- the amount of degradation products of silodosin during storage of the oral drug for 3 months at 30 ° C and 65% air humidity is generally below 0.7 wt .-%, preferably below 0.5 wt .-%, based on the Amount of silodosin.
- the present invention thus relates to a medicament for oral administration, characterized in that the active ingredient silodosin is present in admixture with a basic copolymer.
- silodosin and pharmaceutically acceptable salts thereof are acid addition salts.
- suitable acid addition salts are hydrochlorides, maleates, oxalates, sulfates, methanesulfonates, isothionates, toluenesulfonates, trifluoroacetates, pyruvates, sulfamides, glutamates, glutarates, sorbates and / or succinates.
- silodosin is preferably used in the form of the free base.
- the ratio of the basic copolymer to silodosin is not particularly limited, but the proportion of the basic copolymer is usually at least as high as the content of silodosin.
- the weight ratio of the basic copolymer to silodosin (or the salt thereof) is in the range of 1: 1 to 500: 1, more preferably in the range of 2: 1 to 50: 1.
- the mixture of silodosin or a pharmaceutically acceptable salt thereof may be used as such as an oral drug of the present invention, that is, directly be administered to a patient.
- the pharmaceutical composition according to the invention is first converted into a unit dosage form which is suitable and customary for oral administration. Suitable unit dosage forms are for example sachets, capsules or tablets. According to the invention, tablets and capsules are preferred, capsules in particular being understood as meaning hard gelatin capsules.
- the medicament is preferably a capsule or a tablet, most preferably a tablet or a hard gelatin capsule.
- the mixture of silodosin or a pharmaceutically acceptable salt thereof and the basic copolymer for example, directly or without further auxiliaries and additives, for example, transferred to a sachet or capsule or pressed into a tablet or it can first with suitable further auxiliary and Mixed additives and then filled, for example, in a sachet or capsule or pressed into a tablet.
- auxiliaries or additives can already be used in the preparation of the mixture.
- auxiliaries and additives are known to the person skilled in the art and described, for example, in the European Pharmacopoeia. Possible auxiliaries are, for example, disintegrants, release agents, fillers, binders, additives for improving the powder flowability, lubricants, flow regulators and / or surfactants.
- the medicament according to the invention particularly preferably contains at least one disintegrant, preferably in a content in the range from 1 to 10, preferably from 3 to 6,% by weight.
- An explosive accelerates the disintegration of a dosage form, in particular a tablet, after introduction into water or in contact with the digestive juices.
- Disintegrators preferred according to the invention are organic disintegrants, such as carageenan, croscarmelose, sodium carboxymethyl starch, soy, polysaccharides and crospovidone.
- the medicament according to the invention preferably contains, as disintegrant, a so-called "superdisintegrant", to which in particular crosslinked PVP and count cross-linked sodium starch glycolate.
- Crosslinked PVP is particularly preferably used as disintegrants according to the invention.
- Lubricants are generally used to reduce the sliding friction, which may be particularly advantageous in tableting.
- preferred lubricants are stearic acid, adipic acid, sodium (for example, under the brand Pruv ® distributed) and / or magnesium stearate.
- the content of lubricant is preferably 0-5, more preferably 0.1-5, especially 0.5-3 wt .-%.
- the medicaments according to the invention may also contain binders, for example.
- binders are copovidone, gelatin and hydroxypropylcellulose. Other binders are known to those skilled in the art.
- the content of binder is preferably 0-10, in particular 0.5-10 wt .-%.
- Many compounds belong to both the group of disintegrating agents and to the group of binding agents, for example microcrystalline cellulose. Such a compound may of course also be present in the medicaments according to the invention and, depending on the concentration and other constituents, have the function of a binder or of a disintegrating agent.
- a pharmaceutical composition according to the invention may further contain additives for improving the flowability, preferably in an amount of 0-5, in particular of 1, 5-4 wt .-%.
- additives for improving the flowability preferably in an amount of 0-5, in particular of 1, 5-4 wt .-%.
- An example of such an adjuvant is particulate silicon dioxide, which is marketed for example under the trade name Aerosil ®. Preference is given to silica having a specific surface area of 50-400 m 2 / g, determined by gas absorption in accordance with PH Eur., 6th edition, 2.9.26.
- the temperature and the pH it may be advantageous to the mixture of the basic copolymer and active ingredient to add a surfactant.
- the surfactant is not particularly limited.
- polyoxyethylene sorbitan monooleate, sodium lauryl sulfate, polyoxyethylene (20) sorbitan monolaurate, polyalkylene glycol ethers, etc. may be mentioned.
- Particularly preferred are sodium lauryl sulfate and polyoxyethylene (20) sorbitan monolaurate.
- the medicaments according to the invention may, for example, also contain one or more release agents.
- release agents according to the invention in accordance with the general knowledge materials understood that reduce the agglomeration in the core bed.
- suitable release agents are talc, silica gel, polyethylene glycol (preferably with 2000-10000 g / mol weight average molecular weight) and / or glycerol monostearate.
- fillers which are preferred according to the invention are calcium carbonate, magnesium carbonate, magnesium oxide, calcium sulfate, starch, starch derivatives, modified starch, polysaccharides, chitin, cellulose, cellulose derivatives, calcium phosphate, calcium hydrogenphosphate, sucrose, maltodextrin, dextrate, dextrin, dextrose, lactose, lactose derivatives and hydrogenated vegetable oil.
- Release agent 0-5 - 0-5 0-3 0-3 The mixing of the usual pharmaceutically acceptable excipients with the mixture for the preparation of a unit dosage form can be carried out in conventional manner in conventional mixers, for example a Turbula T10B can ® (Bachhofen AG, Switzerland) can be mentioned.
- the mixing time in commercially available mixers is usually 1 minute to 1 hour, preferably 3 minutes to 20 minutes.
- the medicaments according to the invention are optionally compressed into tablets after the addition of further pharmaceutically acceptable excipients and additives.
- the compression can be done with tableting machines known in the art, such as eccentric presses or concentric presses.
- a pressing force of 2-40 kN, preferably 2.5-35 kN is usually used.
- suitable tablet presses the press fats ® may 102i (Fette GmbH, Germany) are mentioned.
- eccentric presses usually a pressing force of 1 -20 kN, preferably from 2.5 to 10 kN is applied.
- a suitable eccentric press can be called the commercial product Korsch ® EKO.
- the pressing into tablets takes place according to the invention preferably as dry compression.
- the medicaments according to the invention are in the form of tablets which are swallowed whole, it is preferred to coat these tablets with a film layer.
- the above proportions of active ingredient and excipients refer to the uncoated tablet.
- macromolecular substances are used for the film-coating, for example, modified cellulose, polymethacrylates, polyvinylpyrrolidone, polyvinyl acetate phthalate, Zein, Eudragit ® and / or shellac. It is also possible according to the invention to provide the tablets with an enteric coating. Enteric coating materials are known in the art.
- the layer thickness of the tablet coating is preferably 2-100 ⁇ .
- the tablets according to the invention preferably have a tablet height to weight ratio in the range of 0.005-0.3 mm / mg, particularly preferably 0.05-0.2 mm / mg.
- the drug of the present invention preferably contains silodosin or the pharmaceutically acceptable salt thereof in an amount of 0.5 mg to 15 mg, more preferably 2 mg 1 1 mg, in particular from 4 mg to 8 mg.
- the invention thus z.
- oral drugs especially tablets containing 4 mg or 8 mg silodosin or a pharmaceutically acceptable salt thereof.
- the medicaments according to the invention and in particular the tablets according to the invention have outstanding content uniformity which is in the range of 95-105% of the average content, preferably in the range of 98-102% of the average content, particularly preferably in the range from 99-101% of the average salary.
- the content uniformity is determined according to PH Eur. 6.0 Section 2.9.6.
- the tablets according to the invention have a particularly advantageous rapid in vitro release profile.
- the release profile of the tablets according to the invention determined according to the USP Paddle Method Apparatus II, is such that after 60 minutes usually at least 40%, preferably at least 60%, in particular at least 80% of the active ingredient is stirred at a stirring speed of 50 rpm in 0.1 N HCl ( pH 1 .2) at 37 ° C is released.
- the release profile of the tablets according to the invention does not change significantly during storage, which is also a particular advantage of the tablets according to the invention.
- the content data in this application in each case relate to the total weight of the medicament according to the invention, unless otherwise stated or obvious due to the circumstances.
- the mixtures of silodosin or a pharmaceutically acceptable salt thereof and the basic copolymer can be prepared by various techniques. Preferred processes are dry mixing, wet granulation, melt granulation, spray drying, lyophilization and melt extrusion, particularly preferred are wet granulation, melt granulation and spray drying.
- silodosin or a pharmaceutically acceptable salt thereof is mixed with a basic copolymer in the presence of a solvent and optionally further pharmaceutically acceptable excipients. Subsequently, a granulation step is performed. The granules is optionally (preferably) dried and the dried granules are optionally sieved.
- silodosin or a pharmaceutically acceptable salt thereof is introduced together with a basic copolymer and optionally with other pharmaceutically acceptable excipients and additives in a suitable solvent.
- the silodosin or the pharmaceutically acceptable salt thereof may be added to the solvent, and then the basic copolymer may be added, or first, the basic copolymer may be initially charged in a solvent and then the silodosin or the pharmaceutically acceptable salt thereof may be added.
- the basic copolymer and silodosine or a pharmaceutically acceptable salt thereof may be added simultaneously to the solvent.
- the resulting mixture is then homogenized, granulated (optionally using a filler and optionally further active ingredients) and, if appropriate, dried, resulting in the formation of a granulate.
- the granules are dried, optionally sieved to a desired particle size.
- the optionally sieved granules thus obtained represent a preferred embodiment of the medicament according to the invention with the mixture of silodosin or a pharmaceutically acceptable salt thereof and the basic copolymer.
- the choice of the solvent is not particularly limited. All solvents which dissolve or suspend the silodosin or the silodosin salt and the basic copolymer to a sufficient extent are suitable for this purpose.
- a surfactant can be added to improve the solubility of the compounds in the solvent.
- Ethanol, isopropanol or an isopropanol-acetone-water mixture is very particularly preferably used, it being possible for constituents of isopropanol and acetone in the isopropanol-acetone-water mixture to be in the range of 10-90%, more preferably in the range of 70 -30%, most preferably about 50%.
- enough solvent is used to form a solution or suspension of the silodosin or salt thereof and the basic copolymer.
- the formation of the mixture according to the invention takes place in that silodosin or a pharmaceutically acceptable salt thereof, the basic copolymer and optionally further pharmaceutically acceptable additives and optionally a surfactant are introduced into a suitable solvent as explained above and dissolved or suspended ; the solution or suspension is then optionally applied to a filler and granulated.
- a suitable solvent as explained above and dissolved or suspended ; the solution or suspension is then optionally applied to a filler and granulated.
- the suspension already has a suitable consistency to carry out a granulation without the use of another filler. In this case it is preferred to carry out the granulation of the suspension as such.
- the solution or suspension can be applied to a filler as described above and then granulated.
- the granules are optionally dried and optionally sieved to a suitable particle size.
- the granulation is carried out in conventional devices for granulation, eg Diosna P1 / 6, DIOSNA Dierks & Söhne GmbH.
- the granulation is carried out such that the granules have a volume-average particle size (D50 value) in the range of 75-800 ⁇ , more preferably in the range of 100-500 pm.
- the weight average particle size for example, by sieve analysis, for example using a Retsch ® AS 2000 apparatus are determined, wherein an amplitude of 1, 5 seconds, an interval of 10 minutes and a sample weight of 20 g can be given as exemplary measurement condition.
- a D50 value for the volume average particle size means that 50% of the particles are smaller in volume than the D50 value and 50% in volume greater than the D50 value.
- the granules obtained can then be dried in a customary manner, the drying preferably taking place in such a way that the residual solvent content in the granules is at most 0.5%, more preferably at most 0.3%. This is also the preferred content Residual solvent in the medicament of the invention.
- the drying can be carried out in a conventional drying oven, preferably under reduced pressure, at a temperature in the range from 20 to 70 ° C., in particular at 30 to 60 ° C., particularly preferably at 35 to 50 ° C. and over a period of at least one hour, preferably at least one and a half hours, for example about two hours.
- the choice of the drying conditions is not particularly limited.
- a decomposition of the active ingredient is to be feared only when drying for a long time at very high temperatures.
- the silodosin or the pharmaceutically acceptable salt thereof is combined with the basic copolymer and optionally further pharmaceutically acceptable additives in a suitable solvent or in a solvent mixture at a temperature of from 20 to 70 ° C, preferably from 30 to 60 ° C solved. Subsequently, the solution is subjected to spray drying.
- spray-drying is known to the person skilled in the art. In accordance with the invention, any suitable spray drying process can be used using known and commercially available spray drying equipment.
- spray drying is carried out at a suitable temperature. Since it has been found according to the invention that the basic copolymer stabilizes the inherently temperature-sensitive silodosin, spray-drying may be carried out at a suitable higher temperature of above 70 ° C, especially 80 ° C and above, for example at 85 ° C or another suitable for spray drying Temperature be performed. This forms a preferred according to the invention drug.
- silodosin or a pharmaceutically acceptable salt thereof and the basic copolymer preferred according to the invention are dissolved in a suitable solvent or optionally a suitable solvent mixture.
- solvent or solvent mixture the same solvents or solvent mixtures can be used, which were explained above in connection with the first preferred embodiment (granulation).
- a complete solution of the components to be subjected to the spray-drying is present, so that according to the invention only those solvents or solvent mixtures are used in this method, the silodosin or the pharmaceutically acceptable salt thereof and completely dissolve the basic copolymer used (and the optionally further pharmaceutically acceptable auxiliaries and additives).
- a surfactant may be used to improve the solubility.
- the resulting solution is subjected to spray drying according to the invention at a preferred temperature of 30 to 110 ° C., preferably at 50 to 100 ° C., particularly preferably at 70 to 90 ° C.
- Spray-drying may be carried out by means of conventional spray-drying equipment, e.g. with Büchi B-290, Büchi Labortechnik GmbH.
- the spray drying is performed such that the spray dried material has a volume average particle size (D50 value) of ⁇ 15pm, more preferably ⁇ 10m.
- the volume-average particle size is preferably determined by means of a particle meter from Malvern type designation: Mastersizers 2000S.
- the final spray-dried mixture is preferably treated with a suitable pharmaceutically acceptable filling agent, which has optionally been granulated with other pharmaceutically acceptable excipients and additives, and over a period of at least one minute, preferably one to 20 minutes, e.g. mixed over a period of about 5 minutes.
- any known pharmaceutically acceptable filler can be used, as indicated above.
- the silodosin or the pharmaceutically acceptable salt thereof is subjected to melt extrusion with the basic copolymer and optionally with further pharmaceutically acceptable additives.
- the extrudate obtained is comminuted after cooling, sieved to a desired particle size and mixed with other pharmaceutically acceptable additives.
- the product thus obtained is preferably further processed to a unit dosage form, in particular to a tablet or hard gelatin capsule.
- the melt extrusion process takes place at a preferred temperature according to the invention of 40 to 110 ° C., preferably 30 to 90 ° C., more preferably 50 to 70 ° C.
- Melt extrusion can be carried out using melt extruders known in the art, for example HAAKE * PolyLab QC, ThermoFischer Scientific Inc.
- silodosin or a pharmaceutically acceptable salt thereof is mixed with the basic copolymer, optionally with the addition of further pharmaceutically acceptable auxiliaries and additives.
- This mixture is introduced into an extruder and processed there to a homogeneous melt.
- a preferred extruder has a screw profile.
- the screw profile should include kneading blocks, since the shear forces generated by the kneading blocks contribute to the melting of the mixture and thus also to the dissolution of the active ingredient in the excipient.
- the temperature profile is chosen so that the highest temperatures are set in the cylinder in which the kneading blocks are seated.
- the viscosity of the melt can be regulated. There is a minimum temperature for each system, otherwise the nozzle becomes clogged.
- the extrusion is preferably carried out at an outlet pressure of about 20 bar to about 100 bar, in particular from about 20 bar to about 50 bar.
- the following auxiliaries and additives are used: poly (methyl acrylate-co-methyl methacrylate-co-methacrylic acid), poly (methacrylic acid-co-methyl methacrylate) 1: 2, hydroxypropyl cellulose, ethyl cellulose, cellulose acetate butyrate, cellulose acetate phthalate, poly (ethylene oxide), poly (ethylene glycol) , Poly (vinylpyrrolidone), poly (vinylacetate), hydroxypropylmethylcellulose phthalate, polyvinylpyrrolidone-co-vinylacetate, hydroxypropylmethylcellulose,
- Hydroxypropylmethyl cellulose acetate succinate poly (lactide-co-glycolide), polyvinyl alcohol, chitosan lactate, pectin, carbomer, polycarbophil, poly (ethylene-co-vinyl acetate), polyethylenes, poly (vinyl acetate-co-methacrylic acid), polycaprolactone, carnauba wax, ethylene vinyl acetate copolymer , Glycerol palmitostearate, starch, maltodextrin, isomalt, citric acid, sodium bicarbonate, polyvinyl alcohol-polyethylene glycol copolymer.
- the resulting extrudate is typically in strands of different lengths, which are broken after exiting the extruder after cooling.
- the fragments can be comminuted with a mill, eg a centrifugal mill, to obtain fractions of a certain particle size.
- a mill eg a centrifugal mill
- the particle size is 10- 1000 ⁇ . This corresponds at the same time to the particle size of most of the auxiliaries used for the preparation of solid dosage forms, thus enabling a better mixing of the ground extrudate with the excipients.
- small extrudate particles release the active ingredient more quickly than coarse particles.
- a particularly preferred method according to the invention for preparing an oral medicament comprises the following steps: a) introducing the silodosin or a pharmaceutically acceptable salt thereof with a basic copolymer and optionally with further pharmaceutically acceptable additives into a suitable solvent or a solvent mixture;
- Also preferred according to the invention is a process for preparing an oral medicament comprising the steps of a) introducing the silodosine or a pharmaceutically acceptable salt thereof and a basic copolymer, optionally with further pharmaceutically acceptable auxiliaries, into a suitable solvent or a solvent mixture at an optionally elevated temperature of 20 to 70 ° C; b) spray-drying the resulting solution;
- Also preferred according to the invention is a process for preparing an oral medicament comprising the following steps: a) melt extruding the silodosin or a pharmaceutically acceptable salt thereof with the basic copolymer and optionally with further pharmaceutically acceptable excipients;
- a mixture of 12 g silodosin, 62 g Eudragit ® E PO and 6 g of polyvinylpyrrolidone and 6 g of polyethylene glycol was granulated with 80 ml of a mixture of Eudragit ® E 12.5 and 3 g sodium lauryl sulfate and over a period of 2 hours at 40 ° C dried.
- the granules were passed through a 710 pm sieve and then further dried for a further 2 hours.
- To the dried granules was added 420 g of calcium hydrogen phosphate.
- the resulting material was mixed for 15 minutes, then 3 g of magnesium stearate was added and the material was mixed for a further 3 minutes.
- Emdex ® (dextrin) was treated with 4 mg Tween ® 20 (2% based on the total amount of drug), granulated and then (2 mg magnesium stearate) mixed with 1% magnesium stearate. To the previously prepared spray dried material, the mixture Emdex ® was added. The entire mixture was then mixed for a period of 5 minutes. One half was filled into hard gelatin capsules with 8 mg dosage, the other half was compressed into tablets with a dosage of 8 mg.
- silodosin and 100 g of Eudragit ® E 100 were subjected to at maximum temperature you of 60 ° C a melt extrusion process. After cooling, the resulting extrudate was comminuted to a particle size of less than 500 ⁇ m using a mill and sieved. To the powder was added 10 g of sodium bicarbonate, 50 g of calcium hydrogenphosphate and 1 g of magnesium stearate.
- One half was filled into hard gelatin capsules with 8 mg dosage, the other half was compressed into tablets with a dosage of 8 mg.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne un médicament d'administration orale contenant un mélange de silodosine et d'un de ses sels pharmaceutiquement tolérables, et d'un copolymère basique. L'invention concerne également un procédé de production de ce médicament.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11735435.7A EP2595607A2 (fr) | 2010-07-23 | 2011-07-21 | Médicament d'administration orale contenant un mélange de silodosine et d'un copolymère basique |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10170649 | 2010-07-23 | ||
EP11735435.7A EP2595607A2 (fr) | 2010-07-23 | 2011-07-21 | Médicament d'administration orale contenant un mélange de silodosine et d'un copolymère basique |
PCT/EP2011/062566 WO2012010669A2 (fr) | 2010-07-23 | 2011-07-21 | Médicament d'administration orale contenant un mélange de silodosine et d'un copolymère basique |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2595607A2 true EP2595607A2 (fr) | 2013-05-29 |
Family
ID=44628851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11735435.7A Withdrawn EP2595607A2 (fr) | 2010-07-23 | 2011-07-21 | Médicament d'administration orale contenant un mélange de silodosine et d'un copolymère basique |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2595607A2 (fr) |
JP (1) | JP2013532651A (fr) |
WO (1) | WO2012010669A2 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013061338A1 (fr) * | 2011-08-24 | 2013-05-02 | Cadila Healthcare Limited | Compositions pharmaceutiques de silodosine |
US20150140101A1 (en) * | 2012-07-02 | 2015-05-21 | Hetero Research Foundation | Solid oral compositions of silodosin |
TWI659752B (zh) * | 2013-03-26 | 2019-05-21 | 日商橘生藥品工業股份有限公司 | 經遮蔽西羅多辛(Silodosin)苦味之經口投與製劑 |
KR102206104B1 (ko) * | 2014-04-03 | 2021-01-22 | 한미약품 주식회사 | 실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형 |
JPWO2016051782A1 (ja) * | 2014-09-30 | 2017-07-13 | キッセイ薬品工業株式会社 | 苦味を有する薬剤の苦味をマスキングした経口投与製剤 |
JP2016138073A (ja) * | 2015-01-29 | 2016-08-04 | 大原薬品工業株式会社 | 安定性を改善した、シロドシンを含有する錠剤 |
JP2017014119A (ja) * | 2015-06-26 | 2017-01-19 | 東和薬品株式会社 | 経口医薬組成物 |
JP7023600B2 (ja) * | 2016-10-17 | 2022-02-22 | 東和薬品株式会社 | シロドシン含有医薬組成物とその製造方法 |
EP3354283B1 (fr) | 2017-06-20 | 2019-08-07 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Composition de capsule pharmaceutique comprenant de la silodosine |
JP2019070045A (ja) * | 2019-02-06 | 2019-05-09 | 大原薬品工業株式会社 | 安定性を改善した、シロドシンを含有する錠剤 |
CN112933084A (zh) * | 2019-12-10 | 2021-06-11 | 广东东阳光药业有限公司 | 一种赛洛多辛组合物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE122010000031I1 (de) | 1992-12-02 | 2010-10-21 | Kissei Pharmaceutical | Indolin Verbindungen zur Behandlung von Dysurien |
DE19653605C2 (de) | 1996-12-20 | 2002-11-28 | Roehm Gmbh | Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems |
JP4324266B2 (ja) * | 1999-02-26 | 2009-09-02 | キッセイ薬品工業株式会社 | α1Aアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤 |
UA78854C2 (en) | 2002-09-06 | 2007-04-25 | Kissei Pharmaceutical | Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same |
JP4523265B2 (ja) | 2002-11-13 | 2010-08-11 | 旭化成ファーマ株式会社 | 排尿障害治療用口腔内崩壊製剤 |
PL220457B1 (pl) | 2002-12-16 | 2015-10-30 | Kissei Pharmaceutical | Kapsułka do leczenia dysurii |
US20060013880A1 (en) | 2004-07-19 | 2006-01-19 | Robert Femia | Formulation stabilizer for proton pump inhibitors |
-
2011
- 2011-07-21 EP EP11735435.7A patent/EP2595607A2/fr not_active Withdrawn
- 2011-07-21 WO PCT/EP2011/062566 patent/WO2012010669A2/fr active Application Filing
- 2011-07-21 JP JP2013520157A patent/JP2013532651A/ja not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2012010669A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012010669A2 (fr) | 2012-01-26 |
JP2013532651A (ja) | 2013-08-19 |
WO2012010669A3 (fr) | 2012-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2595607A2 (fr) | Médicament d'administration orale contenant un mélange de silodosine et d'un copolymère basique | |
DE69434479T2 (de) | Tramadolhaltiges Arzneimittel mit gesteuerter Wirkstoffabgabe | |
DE69434640T2 (de) | Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe | |
DE60221691T2 (de) | Tamsulosin tabletten ohne nahrungsmitteleffekt | |
EP2355802A1 (fr) | Produits intermédiaires et formes galéniques orales contenant de la lénalidomide | |
WO2009000493A1 (fr) | Procédé de production d'un médicament contenant du tadalafil | |
EP2334284A2 (fr) | Cinacalcet compacté | |
DE102009015702A1 (de) | Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung | |
EP2408431A1 (fr) | Rétigabine solide sous forme non cristalline | |
EP2309995A1 (fr) | Formulation pharmaceutique pour la réduction de la pression artérielle pulmonaire | |
WO2010017918A2 (fr) | Ambrisentan amorphe | |
WO2011047837A2 (fr) | Cinacalcet granulé par fusion | |
EP2203156A2 (fr) | Candesartan cilexetil | |
EP2585050B1 (fr) | Complexe d'inclusion de silodosine et cyclodextrine | |
WO2006092222A1 (fr) | Formes galeniques presentant une biodisponibilite controlee | |
WO2006123213A1 (fr) | Preparations a liberation modifiee de gliclazide | |
WO2011138037A2 (fr) | Tapentadol solide sous forme non cristalline | |
DE202021100039U1 (de) | Ethylcellulose-beschichtete Partikel enthaltend ein Salz aus Tapentadol und Phosphorsäure | |
EP2445484A1 (fr) | Aprépitant sous forme de solution solide | |
DE102008000351B4 (de) | Verfahren zur Herstellung eines Ebastin enthaltenden Granulats sowie einer festen pharmazeutischen Zusammensetzung, Ebastin enthaltendes Granulat und dessen Verwendung | |
KR20150096787A (ko) | N-[5-[2-(3,5-디메톡시페닐)에틸]-2h-피라졸-3-일]-4-[(3r,5s)-3,5-디메틸피페라진-1-일]벤즈아미드의 약학 제제 | |
DE102011053068A1 (de) | Darreichungsform mit stabilisierten Wirkstoffpartikeln | |
EP2732812A1 (fr) | Comprimé de pramipexol à libération prolongée | |
WO2015055564A1 (fr) | Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate | |
EP1686965A2 (fr) | Forme de preparation pharmaceutique solide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20121120 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20131112 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140325 |